Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in:

01-10-2024 | Breast Cancer | Review Article

The treatment landscape of triple-negative breast cancer

Authors: Yi Hu, Chen Wang, Huishi Liang, Jie Li, Qiong Yang

Published in: Medical Oncology | Issue 10/2024

Login to get access

Abstract

Triple-negative breast cancer (TNBC) tumors are biologically aggressive breast cancer. On the molecular level, TNBC is a highly heterogeneous disease; more biotechnologies are gradually being used to advance the understanding of TNBC subtypes and help establish more targeted therapies. Multiple TNBC target-related agents are already approved by the Food and Drug Administration for clinical use, including PI3K/AKT/mTOR inhibitors, PRAP inhibitors, and antibody-drug conjugates. Some innovative approaches, like peptide strategies, also promise to treat TNBC. Currently, the interplay between TNBC tumors and their tumor microenvironment provides a promising prospect for improving the efficacy of immunotherapy. In this review, we summarize the prevalent TNBC subtype methodologies, discuss the evolving therapeutic strategies, and propose new therapeutic possibilities based on existing foundational theories, with the attempt to serve as a reference to further advance tailoring treatment of TNBC.
Literature
1.
2.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13:4429–34.CrossRef
3.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.PubMedCrossRef
4.
Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol OncolJ Hematol Oncol. 2023;16:100.CrossRef
5.
6.
Ricci-Vitiani L, Lombardi DG, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.PubMedCrossRef
7.
O’Conor CJ, et al. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker. Biomark Med. 2018;12(7):813–20.PubMedCrossRef
8.
Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174:1293–308.PubMedPubMedCentralCrossRef
9.
Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. The Breast. 2015;24:S36-40.PubMedCrossRef
10.
Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142–50.PubMedPubMedCentralCrossRef
11.
Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer–deciphering the heterogeneity. Clin Cancer Res: Offic J Am Assoc for Cancer Res. 2014;20:782–90.CrossRef
12.
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688–98.PubMedCrossRef
13.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.PubMedPubMedCentralCrossRef
14.
Jiang Y-Z, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428-440.e5.PubMedCrossRef
15.
Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16(1):64.PubMedPubMedCentralCrossRef
16.
Li Y, Rogoff HA, Keates S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA. 2015;112(6):1839–44.PubMedPubMedCentralCrossRef
17.
Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569:560–4.PubMedCrossRef
18.
Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017;49:1476–86.PubMedPubMedCentralCrossRef
19.
Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2012;12:68–78.CrossRef
20.
21.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394–405.PubMedPubMedCentralCrossRef
22.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.PubMedPubMedCentralCrossRef
23.
Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2021;32:240–9.CrossRef
24.
25.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2017;390:1949–61.CrossRef
26.
Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26:4282–8.PubMedPubMedCentralCrossRef
27.
Patsouris A, Tredan O, et al. RUBY: a phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD). J Clin Oncol. 2019;37:1092–1092.CrossRef
28.
Chu Y, Zhou X, Wang X. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J Hematol OncolJ Hematol Oncol. 2021;14:88.CrossRef
29.
Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol OncolJ Hematol Oncol. 2019;12:94.CrossRef
30.
31.
Son S, Shin S, Rao NV, et al. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy. Int J Biol Macromol. 2018;110:406–15.PubMedCrossRef
32.
Aditya B, Mayer IA, Vahdat LT, Tolaney SM, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–51.CrossRef
33.
Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:5131–8.CrossRef
34.
Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32:1148–56.PubMedCrossRef
35.
Tringler B, Zhuo S, Pilkington G, Torkko KC, et al. B7-H4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:1842–8.CrossRef
36.
Chambers CA, Kuhns MS, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565–94.PubMedCrossRef
37.
Toader D, Fessler SP, Collins SD, Conlon PR, Bollu R, Catcott KC, et al. Discovery and preclinical characterization of XMT-1660, an optimized B7-H4-targeted antibody-drug conjugate for the treatment of cancer. Mol Cancer Ther. 2023;22:999–1012.PubMedPubMedCentralCrossRef
38.
Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.PubMedCrossRef
39.
Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7–24.PubMedPubMedCentralCrossRef
40.
Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, et al. PIK3CA, and PTEN aberrations in early-phase trials with PI3K/AKT/mTOR inhibitors: experience with 1656 patients at MD anderson cancer center. Cell Rep. 2014;6:377–87.PubMedPubMedCentralCrossRef
41.
Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRef
42.
Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74–88.PubMedCrossRef
43.
44.
Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30:1051–60.PubMedCrossRef
45.
Dent R, Kim S-B, Oliveira M, Barrios C, O’Shaughnessy J, Isakoff SJ, et al. Abstract GS3-04: double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. Cancer. 2021;81:GS3-04. https://​doi.​org/​10.​1158/​1538-7445.​SABCS20-GS3-04.CrossRef
46.
Baselga J, et al. SANDPIPER: phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors. J Clin Oncol. 2015;33:629–629.
47.
Dreyling M, Santoro A, Mollica L, Leppä S, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35:3898–905.PubMedCrossRef
48.
Guo Z, Luo J, et al. Evaluation of copanlisib in combination with eribulin in triple-negative breast cancer patient-derived xenograft models. Cancer Res Commun. 2024;4(6):1430–40.PubMedPubMedCentralCrossRef
49.
50.
Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008;27:5511–26.PubMedCrossRef
51.
Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell JC, Spicer J, Kwak EL, et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:1888–95.CrossRef
52.
Wu X, Xu Y, Liang Q, Yang X, Huang J, Wang J, et al. Recent advances in dual PI3K/mTOR inhibitors for tumour treatment. Front Pharmacol. 2022;13:875372.PubMedPubMedCentralCrossRef
53.
Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, et al. A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov. 2017;7:102–13.PubMedCrossRef
54.
Lin F-M, Yost SE, Wen W, Frankel PH, Schmolze D, Chu P-G, et al. Differential gene expression and AKT targeting in triple negative breast cancer. Oncotarget. 2019;10:4356–68.PubMedPubMedCentralCrossRef
55.
Kim S-B, Dent R, Im S-A, Espié M, Blau S, Tan AR, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18:1360–72.PubMedPubMedCentralCrossRef
56.
Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho JL, et al. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019;30:1289–97.PubMedCrossRef
57.
Esumi H, Lu J, Kurashima Y, Hanaoka T. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci. 2004;95:685–90.PubMedCrossRef
58.
Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126:955–68.PubMedCrossRef
59.
60.
Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D’Incalci M, et al. Targeting triple-negative breast cancer: Is p53 the answer? Cancer Treat Rev. 2013;39:541–50.PubMedCrossRef
61.
Gadhikar MA, Sciuto MR, Alves MVO, Pickering CR, Osman AA, Neskey DM, et al. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther. 2013;12:1860–73.PubMedPubMedCentralCrossRef
62.
Ma CX, Cai S, Li S, Ryan CE, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest. 2012;122:1541–52.PubMedPubMedCentralCrossRef
63.
Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, et al. A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2011;67:1225–37.PubMedCrossRef
64.
Ho AL, et al. Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. J Clin Oncol. 2011;29:3033–3033.CrossRef
65.
Wellenstein MD, Coffelt SB, Duits DEM, van Miltenburg MH, et al. Loss of p53 triggers Wnt-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019;572:538–42.PubMedPubMedCentralCrossRef
66.
Lang GA, Iwakuma T, Suh Y-A, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome. Cell. 2004;119:861–72.PubMedCrossRef
67.
Peuget S, Zhou X, Selivanova G. Translating p53-based therapies for cancer into the clinic. Nat Rev Cancer. 2024;24:192–215.PubMedCrossRef
68.
Sarig R, Rivlin N, Brosh R, Bornstein C, et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med. 2010;207:2127–40.PubMedPubMedCentralCrossRef
69.
Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, et al. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 2022;7:100573.PubMedPubMedCentralCrossRef
70.
Sharma A, Comstock CE, et al. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res. 2007;67(13):6192–203.PubMedPubMedCentralCrossRef
71.
Jones RA, Robinson TJ, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest. 2016;126(10):3739–57.PubMedPubMedCentralCrossRef
72.
Wonder E, Simón-Gracia L, et al. Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo. Biomaterials. 2018;166:52–63.PubMedPubMedCentralCrossRef
73.
Adams GP, Schier R, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61(12):4750–5.PubMed
74.
Huang Y, Zeng A, Song L. Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer. Front Immunol. 2023;14:1255820.PubMedPubMedCentralCrossRef
75.
Mulkearns-Hubert EE, et al. Targeting NANOG and FAK via Cx26-derived cell-penetrating peptides in triple-negative breast cancer. Mol Cancer Ther. 2024;23(1):56–67.PubMedPubMedCentralCrossRef
76.
Thiagarajan PS, Sinyuk M, et al. Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun. 2018;9(1):578.PubMedPubMedCentralCrossRef
77.
McHenry PR, Prosperi JR. Proteins found in the triple-negative breast cancer secretome and their therapeutic potential. Int J Mol Sci. 2023;24(3):2100.PubMedPubMedCentralCrossRef
78.
Mantovani A, Locati M, Vecchi A, et al. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 2001;22(6):328–36.PubMedCrossRef
79.
O’Neill LA, Dinarello CA. The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today. 2000;21:206–9.PubMedCrossRef
80.
So JY, Ohm J, Lipkowitz S, Yang L. Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options. Pharmacol Ther. 2022;237:108253.PubMedPubMedCentralCrossRef
81.
Dey P, Rathod M, De A. Targeting stem cells in the realm of drug-resistant breast cancer. Breast Cancer (Dove Med Press). 2019;11:115–35.PubMed
82.
Chekhun SV, Zadvorny TV, et al. CD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes. Exp Oncol. 2015;37(1):58–63.PubMedCrossRef
83.
Chuthapisith S, Eremin J, et al. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol. 2010;19(1):27–32.PubMedCrossRef
84.
Park SY, LeeHE, et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res. 2010;16(3):876–87.PubMedPubMedCentralCrossRef
85.
Lehmann BD, BauerJA, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.PubMedPubMedCentralCrossRef
86.
Yu F, Yao H, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.PubMedCrossRef
87.
88.
Lapidot T, Sirard C, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–8.PubMedCrossRef
89.
Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254–67.PubMedCrossRef
90.
91.
Joshi M, Dey P, et al. Recent advancements in targeted protein knockdown technologies-emerging paradigms for targeted therapy. Explor Target Antitumor Ther. 2023;4(6):1227–48.PubMedPubMedCentralCrossRef
92.
93.
Cromm PM, Samarasinghe KTG, et al. Addressing kinase-independent functions of Fak via PROTAC-mediated degradation. J Am Chem Soc. 2018;140:17019–26.PubMedCrossRef
94.
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–50.PubMedPubMedCentralCrossRef
95.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.PubMedCrossRef
96.
Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019;129:1785–800.PubMedPubMedCentralCrossRef
97.
Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib keynote-012 study. J Clin Oncol. 2016;34:2460–7.PubMedPubMedCentralCrossRef
98.
Voorwerk L, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920–8.PubMedCrossRef
99.
Dirix LY, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–86.PubMedCrossRef
100.
Dai M, Liu M, Yang H, Küçük C, You H. New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. Exp Hematol Oncol. 2022;11:101.PubMedPubMedCentralCrossRef
101.
Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174:1373-1387.e19.PubMedPubMedCentralCrossRef
102.
Ali HR, Glont S-E, Blows FM, Provenzano E, Dawson S-J, Liu B, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol Off J Eur Soc Med Oncol. 2015;26:1488–93.CrossRef
103.
Adams S, Loi S, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405–11.PubMedCrossRef
104.
Winer EP, Lipatov O, Im S-A, Goncalves A, Muñoz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:499–511.PubMedCrossRef
105.
Galluzzi L, Humeau J, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725–41.PubMedCrossRef
106.
Schmid P, Adams S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.PubMedCrossRef
107.
Roussos Torres ET, Ho WJ, et al. Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nat Cancer. 2024;5(6):866–79.PubMedCrossRef
108.
Zhang Y, Chen J, et al. The role of histone methylase and demethylase in antitumor immunity: a new direction for immunotherapy. Front Immunol. 2023;13:1–16.CrossRef
109.
Shimomura A, Fujiwara Y, et al. Tremelimumab-associated tumor regression following after initial progression: two case reports. Immunotherapy. 2016;8(1):9–15.PubMedCrossRef
110.
Klimovich B, Meyer L, Merle N, Neumann M, König AM, Ananikidis N, et al. Partial p53 reactivation is sufficient to induce cancer regression. J Exp Clin Cancer Res CR. 2022;41:80.PubMedCrossRef
111.
Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019;48:4361–74.PubMedCrossRef
112.
Metadata
Title
The treatment landscape of triple-negative breast cancer
Authors
Yi Hu
Chen Wang
Huishi Liang
Jie Li
Qiong Yang
Publication date
01-10-2024
Publisher
Springer US
Published in
Medical Oncology / Issue 10/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02456-9

Other articles of this Issue 10/2024

Medical Oncology 10/2024 Go to the issue

Review Article

The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review

Comment

Letter to the editor: comment on “Chitosan-loaded piperlongumine nanoparticles and kaempferol enhance the anti-cancer action of doxorubicin in targeting of Ehrlich solid adenocarcinoma: in vivo and in silico modeling study”

Comment

Letter to the editor: comment on “Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment”

Editorial

Comment on “2-methoxyestradiol sensitizes tamoxifen-resistant MCF-7 breast cancer cells via downregulating HIF-1α”

Review

How mitochondrial dynamics imbalance affects the progression of breast cancer:a mini review

Review

The role of IL-22 in cancer

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits